ANNX — Annexin Pharmaceuticals AB (publ) Income Statement
0.000.00%
Last trade - 00:00- SEK98.12m
- SEK70.73m
Annual income statement for Annexin Pharmaceuticals AB (publ), fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 51.2 | 40.7 | 44.2 | 50.5 | 37.4 |
| Operating Profit | -51.2 | -40.7 | -44.2 | -50.5 | -37.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -52.1 | -40.7 | -44.1 | -50.3 | -36.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -52.1 | -40.7 | -44.1 | -50.3 | -36.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -52.1 | -40.7 | -44.1 | -50.3 | -36.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -52.1 | -40.7 | -44.1 | -50.3 | -36.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -35.2 | -15.4 | -24.1 | -10.9 | -5.58 |
| Dividends per Share |